Unknown PHASE2 INTERVENTIONAL 1-arm NCT04111380

Efficacy and Safety Study of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers

Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers: a Prospective, Open Label, Single-arm Phase II Trial

Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Conditions Advanced Biliary Tract Cancers

Interventions cisplatin and nab-paclitaxel

Updated 6 times since 2019 Last updated: Sep 30, 2019 Started: Sep 24, 2019 Primary completion: Mar 31, 2023 Completion: Sep 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Advanced Biliary Tract Cancers and is currently ongoing. CSPC Ouyi Pharmaceutical Co., Ltd. leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Oct 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2023 [monthly]

Recruiting PHASE2
Apr 2020 — Jan 2021 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Nov 2019 — Apr 2020 [monthly]

Recruiting PHASE2

First recorded

Sep 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSPC Ouyi Pharmaceutical Co., Ltd.
Henan Provincial People's Hospital

Data source: Henan Provincial People's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zhengzhou, China